Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Australia’s losing the blood cancer fight… urgent action needed to save lives

Leukaemia Foundation 4 mins read

The Leukaemia Foundation is today calling for urgent action revealing blood cancer is set to become Australia’s most common and deadly cancer within a decade[i] unless we act now.

 

Fuelling the issue is that while incidence of blood cancer has increased by 79% in the past 20 years[ii], only 12% of blood cancer research funding in that time has gone towards prevention and early detection of the disease[iii] – proportionally well below that of other leading cancers in Australia.

 

With incidence and mortality on track to almost double by 2035[iv], blood cancer will become one of Australia’s most significant public health issues and the most prevalent and deadly form of cancer in the country.

 

You cannot prevent blood cancer, nor can you screen for it or make lifestyle changes to alter your risk of being diagnosed - it's Australia's silent and hidden cancer crisis.

 

According to the Leukaemia Foundation CEO, Chris Tanti, while blood cancer research to date has made significant strides in terms of improving treatment and care options, unfortunately the issue of prevention and early detection of the disease remains unsolved.

 

“Australia is currently facing a blood cancer storm with the disease on track to overtake all other cancers in this country,” said Mr Tanti.

 

“Unlike most other prevalent cancers like lung, breast, prostate, skin, and bowel, you cannot currently screen for, prevent or reduce your risk of being diagnosed with blood cancer. We simply don’t have the knowledge or tools to enable us to do so.”

 

The Leukaemia Foundation believes the two most critical steps to reverse the impact of blood cancer in Australia includes more investment into blood cancer research that focuses on prevention and early detection, and an increase in support services for patients and their loved ones.

 

“With an approximate one in twelve Australians set to be diagnosed with blood cancer in their lifetime[v], being able to diagnose and treat the disease earlier, and provide the best possible support to those impacted, is going to make a significant impact on the rising incidence and mortality rates in Australia,” added Mr Tanti.

 

“We have a once-in-a-generation opportunity to build a national and strategic approach to tackling blood cancer by taking action, together with the Australian blood cancer community, now.

 

“Sadly, failure to invest in blood cancer research which focuses on screening and prevention, as well as greater support services for all patients, will result in an unnecessary loss of life in the future, and a heartbreaking toll on the increasing number of Australians impacted by the disease.”

 

Since 2000, the Leukaemia Foundation's national research program has funded over 365 blood cancer research grants, representing over $87.1 million in research funding, and we are currently investing in projects with a focus on prevention and early detection.

 

However, with a significant underinvestment in blood cancer prevention and early detection compared to other leading cancers in Australia, further investment is immediately needed.

 

“When compared to other leading cancers in Australia, the investment in blood cancer research focused on prevention and early detection is vastly different and contributes to why the incidence of blood cancer is significantly increasing and outpacing that of all other cancers.

 

“For comparison, the percentage share of research investment in prevention, early detection and diagnosis in cervical cancer is 90%, melanoma 55%, lung cancer 37%, prostate cancer 32%, bowel cancer 27% and breast cancer 22%. Drastically behind is blood cancer at only 12%.”[i]

 

Blood cancer currently represents the second leading cause of cancer deaths in this country, and a further 150,000 Australians[vi] of all ages from young babies to older adults, are already living with the disease.

 

To help close the gap, the Leukaemia Foundation is calling for urgent support from everyday Australians to raise vital funds for blood cancer research, and for the services they provide to patients and their loved ones, through its iconic fundraising campaign, the World’s Greatest Shave, which launches across the nation today.

 

The Leukaemia Foundation heavily relies on the generosity of the Australian community to sign up to shave, cut, or colour their hair and fundraise during World’s Greatest Shave so they can continue their support for the growing number of Australians living with blood cancer.

 

“The Leukaemia Foundation has a bold goal to raise $12 million dollars through this year's World's Greatest Shave and we cannot do it alone,” said Mr Tanti.  

 

“We urge Australians to sign up and take part so that we can continue to invest in vital blood cancer research and further support patients and their loved ones when they need it most.”

 

To be counted in the fight against blood cancer and improve outcomes for Australians living with the disease, register to participate in the World’s Greatest Shave at worldsgreatestshave.com or call 1800 500 088.

 

-END-




About us:

About the Leukaemia Foundation: The Leukaemia Foundation stands with Australia to help cure and conquer blood cancer – with care. Together we are attacking every blood cancer, from every direction, in every way we can. We stand beside every Australian to be their voice and their someone-to-turn to, fighting to get them access to the best care. We also accelerate research that is delivering rapid advancements in blood cancer diagnosis and treatments. Plus, we provide services and support that empower people living with any blood cancer to live well after diagnosis. You can learn more about the Leukaemia Foundation and blood cancer at leukaemia.org.au


Contact details:

Please contact the Leukaemia Foundation Media Team via [email protected] or call 0473 154 079. 

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.